comparemela.com

Latest Breaking News On - Tempest therapeutics - Page 3 : comparemela.com

Brokers Set Expectations for Tempest Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TPST)

Brokers Set Expectations for Tempest Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TPST)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

William-blair
Geode-capital-management
Jefferies-financial-group
Susquehanna-international-group
Scotiabank
Tempest-therapeutics-inc
Maytech-global-investments
Millennium-management
Nasdaq
Worth-venture-partners
Tempest-therapeutics
Free-report

Tempest Therapeutics (NASDAQ:TPST) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $47.00 price objective on the stock. HC Wainwright also issued estimates for Tempest Therapeutics’ Q1 2024 earnings at ($0.36) EPS, Q2 2024 earnings at ($0.36) […]

Worth-venture-partners
Scotiabank
Jefferies-financial-group
Tempest-therapeutics-inc
Tempest-therapeutics-company-profile
Northern-trust-corp
Maytech-global-investments
Renaissance-technologies
Sectoral-asset-management-inc
Tempest-therapeutics
Free-report

Tempest Therapeutics (NASDAQ:TPST) Receives Outperform Rating from William Blair

Tempest Therapeutics (NASDAQ:TPST) Receives Outperform Rating from William Blair
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

William-blair
Sectoral-asset-management-inc
Scotiabank
Renaissance-technologies
Tempest-therapeutics-inc
Jefferies-financial-group
Susquehanna-international-group
Millennium-management
Geode-capital-management
Tempest-therapeutics
Free-report
Financial-group

Tempest Therapeutics (NASDAQ:TPST) Trading Down 4.9%

Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report)’s share price traded down 4.9% on Thursday . The stock traded as low as $3.41 and last traded at $3.50. 488,163 shares were traded during trading, a decline of 31% from the average session volume of 710,658 shares. The stock had previously closed at $3.68. Analyst Upgrades […]

Nasdaq
Tempest-therapeutics-inc
Worth-venture-partners
Susquehanna-international-group
Tempest-therapeutics-company-profile
Maytech-global-investments
Millennium-management
Jefferies-financial-group
Geode-capital-management
Tempest-therapeutics
Get-free-report

vimarsana © 2020. All Rights Reserved.